SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-24-003916
Filing Date
2024-02-13
Accepted
2024-02-13 16:25:18
Documents
50
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q vtgn20231231_10q.htm   iXBRL 10-Q 1104435
2 EXHIBIT 31.1 ex_622478.htm EX-31.1 11826
3 EXHIBIT 31.2 ex_622479.htm EX-31.2 11755
4 EXHIBIT 32 ex_622480.htm EX-32 4865
  Complete submission text file 0001437749-24-003916.txt   3781622

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20231231.xsd EX-101.SCH 38070
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20231231_def.xml EX-101.DEF 242734
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20231231_lab.xml EX-101.LAB 212155
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20231231_pre.xml EX-101.PRE 260893
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vtgn-20231231_cal.xml EX-101.CAL 25894
52 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20231231_10q_htm.xml XML 323313
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37761 | Film No.: 24626409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)